Watch as Dr. Thomas Zeller reviews his presentation on the treatment of symptomatic femoropopliteal disease with drug-coated balloons vs bare-metal stents, which he gave at the Amputation Prevention Symposium in August 2023.
Zeeshan S. Husain, DPM, FACFAS, FASPS; Athanasios Garbis, DPM; Cody Ingram, DPM, MPH; Nicolas J. Mouawad, MD, MPH, MBA
This case report details the successful management of a 51-year-old man with CLTI and nondiabetic Charcot neuroarthropathy who underwent major arterial bypass procedures followed by invasive left Charcot foot reconstruction.
This case report details the successful management of a 51-year-old man with CLTI and nondiabetic Charcot neuroarthropathy who underwent major arterial bypass procedures followed by invasive left Charcot foot reconstruction.
This narrative review summarizes the practical applications and limitations of IVUS and EVUS in contemporary endovascular therapy for peripheral arterial disease.
This narrative review summarizes the practical applications and limitations of IVUS and EVUS in contemporary endovascular therapy for peripheral arterial disease.
Drs Lobato and Ysa review the article "A Systematic Review of Clinical Trials in Patients With Critical Limb-Threatening Ischemia” by Nagarsheth et al.
Drs Lobato and Ysa review the article "A Systematic Review of Clinical Trials in Patients With Critical Limb-Threatening Ischemia” by Nagarsheth et al.
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant...
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant...
